| Name | Title | Contact Details |
|---|
Artios is a leading DNA Damage Response (DDR) company focused on developing first-in-class treatments for cancer. The Company is led by an experienced leadership team with world class scientific capabilities and proven expertise in DDR drug discovery, including the identification and development of the PARP inhibitor olaparib. It has a unique partnership with Cancer Research UK (CRUK), and collaborations with leading DNA repair researchers worldwide, such as The Institute of Cancer Research (ICR), London, the Netherlands Cancer Institute (NKI) and The Francis Crick Institute, London. Artios is building a pipeline of next-generation DDR programmes to target hard to treat cancers which will move into Phase 1 clinical studies in 2021. These include ATR inhibitor ART0380 for treating DDR defective tumours and the first-in-class Pol theta inhibitor ART4215 for mono therapy and combination treatments. In December 2020, Artios entered into a global three-year strategic research collaboration with Merck KGaA, Darmstadt, Germany to identify and develop precision oncology medicines targeting nucleases. Artios is backed by blue chip investors including: AbbVie Ventures, Andera Partners, Arix Bioscience plc, IP Group plc, Life Science Partners (LSP), M Ventures, Novartis Venture Fund (NVF), Pfizer Ventures and SV Health Investors. Artios is based at the Babraham Research Campus in Cambridge, UK, with an office in New York City, USA.
LimaCorporate is a medical device company. LimaCorporate’s product range includes Large Joint Primary and Revision implants, Extremities and Fixation solutions and dedicated Patient-Specific prostheses division.
PCI Synthesis is a custom chemical manufacturer of new chemical entities (NCEs), generic APIs, and other specialty chemical products.
Aridis is a privately held biotechnology company located in San Jose, CA, USA which is focused on infectious diseases. Aridis has a strong portfolio of anti-infective product candidates, a human monoclonal antibody discovery platform technology, and best-in-class formulation technologies available for partnering. Our product portfolio comprises two monoclonal antibodies currently at Phase 2 clinical testing in patients, and two additional anti-infective drug candidates entering the IND development stage. Aridis’ suite of anti-infective monoclonal antibodies offers opportunities to profoundly impact current approaches to infection control. Aridis has raised over $20m in grant funding from leading institutions such as the National Institutes of Health, US Dept. of Defense, US Dept. of Health and Human Services’ BARDA, USAID, PATH/Gates Foundations, and Regional Centers of Excellence.
Raland Technologies is a Fairport, NY-based company in the Healthcare, Pharmaceuticals, and Biotech sector.